vTv Therapeutics Statistics
Share Statistics
vTv Therapeutics has 2.62M
shares outstanding. The number of shares has increased by 7.37%
in one year.
| Shares Outstanding | 2.62M |
| Shares Change (YoY) | 7.37% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 4.23% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 1,162 |
| FTD / Avg. Volume | 5.11% |
Short Selling Information
The latest short interest is 21.63K, so 0.83% of the outstanding
shares have been sold short.
| Short Interest | 21.63K |
| Short % of Shares Out | 0.83% |
| Short % of Float | 2.07% |
| Short Ratio (days to cover) | 1.86 |
Valuation Ratios
The PE ratio is -4.32 and the forward
PE ratio is -5.27.
vTv Therapeutics's PEG ratio is
0.06.
| PE Ratio | -4.32 |
| Forward PE | -5.27 |
| PS Ratio | 78.37 |
| Forward PS | 1.3 |
| PB Ratio | 6.53 |
| P/FCF Ratio | -3.15 |
| PEG Ratio | 0.06 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for vTv Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.34,
with a Debt / Equity ratio of 0.01.
| Current Ratio | 7.34 |
| Quick Ratio | 7.34 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | -0.01 |
| Debt / FCF | -0.01 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $44,217.39 |
| Profits Per Employee | $-802,695.65 |
| Employee Count | 23 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 100K |
| Effective Tax Rate | -0.44% |
Stock Price Statistics
The stock price has increased by -25.56% in the
last 52 weeks. The beta is 0.77, so vTv Therapeutics's
price volatility has been higher than the market average.
| Beta | 0.77 |
| 52-Week Price Change | -25.56% |
| 50-Day Moving Average | 18.98 |
| 200-Day Moving Average | 16.18 |
| Relative Strength Index (RSI) | 53.57 |
| Average Volume (20 Days) | 22,744 |
Income Statement
In the last 12 months, vTv Therapeutics had revenue of 1.02M
and earned -18.46M
in profits. Earnings per share was -3.2.
| Revenue | 1.02M |
| Gross Profit | 928K |
| Operating Income | -24.18M |
| Net Income | -18.46M |
| EBITDA | -22.52M |
| EBIT | -22.61M |
| Earnings Per Share (EPS) | -3.2 |
Full Income StatementBalance Sheet
The company has 36.75M in cash and 169K in
debt, giving a net cash position of 36.58M.
| Cash & Cash Equivalents | 36.75M |
| Total Debt | 169K |
| Net Cash | 36.58M |
| Retained Earnings | -299.72M |
| Total Assets | 32.03M |
| Working Capital | 27.6M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -25.31M
and capital expenditures 0, giving a free cash flow of -25.31M.
| Operating Cash Flow | -25.31M |
| Capital Expenditures | n/a |
| Free Cash Flow | -25.31M |
| FCF Per Share | -4.39 |
Full Cash Flow StatementMargins
Gross margin is 91.25%, with operating and profit margins of -2377.58% and -1815.34%.
| Gross Margin | 91.25% |
| Operating Margin | -2377.58% |
| Pretax Margin | -2222.71% |
| Profit Margin | -1815.34% |
| EBITDA Margin | -2213.96% |
| EBIT Margin | -2377.58% |
| FCF Margin | -2488.4% |
